专家访谈 心脑血管 综合领域 作者未知 来源:未知 2009/11/24 18:13:00    加入收藏
内容概要:We are in a kind of discovery and with some part of programs that are advancing in knowledge very rapidly, perhaps in five years we will have enough genetic information to put it all together and then if it is a comprehensive assessment that we can do with genetics then it would make sense to start applying it clinically but right now we are just scratching the surface.

    International Diabetes : Atherogenic dyslipidemia (AD) is characterized by elevated serum triglyceride.  The Farmington Heart study seems to identify with multiple genes that modulate AD susceptibility.  What should be suggested to patients with abnormal genes before they develop dyslipidemia? 

    Dr Krauss:  We have done actually in a another study, the Malmo study that have pinpointed genetic traits associated with features of atherogenic dyslipidemia which includes high levels of small LDL particles together with low HDL and higher triglycerides.  Those are the measurements that we really advocate.  The genetic studies give us a lot of information about the underlying basis for the disorder itself and how variations affects individuals who may be more or less susceptible to this condition but we are not at the point yet to at least in the programs I am involved with, recommend genetic testing per se, but I think it is important to measure the particles in many individuals who may have normal lipids and normal LDLs or even low LDL cholesterol and borderline HDL and borderline triglycerides.  In those individuals we can learn a lot by dissecting the individual components of this syndrome. 

[1]  [2]  [3]  [4]  [5]  [6]  下一页


网友评论仅供其表达个人看法,并不表明国际糖尿病同意其观点或证实其描述。 发表评论需登陆



关于本站 | 设为首页 | 加入收藏 | 站长邮箱 | 友情链接 | 版权申明


国际糖尿病 版权所有  2008-2010 idiabetes.com.cn  All Rights Reserved